Picroside II prevents inflammation injury in mice with diabetic nephropathy via TLR4/NF-κB pathway

Chunmei Ma¹ and Aijie Shi²*

¹Department of Integrated traditional Chinese and Western Medicine, Jinan Central Hospital, Jinan City, Shandong Province, China; ²Department of Renal Medicine, Tianjin Dongli Hospital, Tianjin, China

*Corresponding author: Aijie Shi, Department of Renal Medicine, Tianjin Dongli Hospital, No. 245 Jintang Road and East of the Outer Ring Crossing, Tianjin 300300, China. Email: ajshi9485@163.com

Received: 29 September 2021; Accepted: 26 October 2021; Published: 27 November 2021

© 2021 Codon Publications

Original Article

Abstract

The purpose of this study was to investigate the therapeutic effects of picroside II on diabetic nephropathy and reveal the involved underlying signal pathway. Male Sprague–Dawley (SD) mice were used to construct an animal model of streptozotocin (STZ)-induced diabetic nephropathy. Body weight and fasting blood glucose values were recorded. Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of proteinuria, blood urea nitrogen (BUN), serum creatinine (Scr), interleukin (IL)-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1) and necrosis factor alpha (TNF-α). Protein expression was determined using Western blotting test. Hematoxylin and eosin (H&E) staining was used to examine the morphological changes in kidney tissues. Treatment with picroside II (10 and 20 mg/kg) increased the STZ-induced reduction in body weight of diabetic mice. It also reversed the elevation of fasting blood glucose in STZ-induced diabetic mice. The levels of proteinuria, BUN and Scr were significantly increased in STZ-induced diabetic mice and these increments were prevented by picroside II. The serum levels of MCP-1, IL-1β, IL-6 and TNF-α were reduced, and the morphological damage was lessened by Picroside II in mice with diabetic nephropathy. Besides, picroside II prevented the activation of TLR4/NF-κB pathway. This study proved that picroside II inhibited inflammatory response and prevented kidney injury in mice with diabetic nephropathy through modulation of TLR4/NF-κB pathway, indicating beneficial effect of picroside II on diabetic nephropathy.

Keywords: picroside II; inflammation injury; diabetic nephropathy; TLR4/NF-κB pathway

Introduction

Diabetic nephropathy is one of the complications caused by diabetes mellitus, primarily contributing to the end-stage renal failure worldwide (Umanath and Lewis, 2018). Around 30–40% of diabetic patients develop diabetic nephropathy, and its incidence and related deaths have increased rapidly in the past decades (Umanath and Lewis, 2018; Xiong and Zhou, 2019). Hypertension and hyperglycemia are two major risk factors of diabetic nephropathy (John, 2016). Therefore, treatment strategies of diabetic nephropathy include the following: reduction of cardiovascular risk, decrease of blood glucose and blood pressure, and inactivation of renin–angiotensin–aldosterone system (RAAS) (Umanath and Lewis, 2018). Accumulating evidence has revealed that the pathogenesis of diabetic nephropathy is associated with the activation of inflammatory pathways (Wada and Makino, 2013). Thus, anti-inflammatory therapy is also a potential treatment strategy for diabetic nephropathy.

Toll-like receptor 4 (TLR4)/nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) pathway is an essential inflammatory pathway activated by elevation of reactive oxygen species (ROS), which are produced by activation of RAAS (Xiong and Zhou, 2019). After stimulation, TLR4 transduces the signal and activates the downstream NF-κB signal pathway (Ni et al., 2020). As a transcription factor, activation of NF-κB regulated inflammatory gene expression, including increasing pro-inflammatory
and reducing anti-inflammatory cytokines, resulting in the enhancement of inflammatory response (Zusso et al., 2019). TLR4/NF-κB pathway has been proved to play a key role in diabetic nephropathy-related inflammation (Kintu et al., 2019; Yang et al., 2017). Therefore, inactivation of TLR4/NF-κB pathway is important to prevent the progression of diabetic nephropathy.

Picroside II is a bioactive flavonoid extracted from *Pseudolysimachion rotundum var. subintegrum* (Plantaginaceae), a traditional Chinese herb with anti-inflammatory properties (Lee et al., 2019). Picroside II has demonstrated its anti-inflammatory effects through multiple signaling pathways in various inflammatory disorders. For example, Picroside II ameliorated airway inflammation through GATA/Th2 pathway in house dust mites (HDM)-induced allergic asthma (Choi et al., 2016). Picroside II prevented the kidney by the repression of TLR4/NF-κB pathway in oxidative stress-induced renal ischemia and reperfusion injury (Wang et al., 2015). However, no study has explored the role of picroside II in regulating TLR4/NF-κB pathway during the progression of diabetic nephropathy. Therefore, the purpose of this study was to investigate the therapeutic effects of picroside II in diabetic nephropathy and reveal the involved underlying signal pathway, aiming to provide a new complimentary treatment option for diabetic nephropathy.

**Methods**

**Animal model**

Male Sprague–Dawley (SD) mice (180–220 g, n = 24) were provided by Shandong Experimental Animal Center (Jinan city, Shandong Province, China). The mice were raised at 23°C ± 2°C in a humidity of 40% ± 5% under 12-h light–dark cycle for 1 week to accommodate new environment. Ethical approval was obtained from the Ethics Committee of Qilu Hospital of Shandong University. All animal procedures were conducted in compliance with the ethical standards under the protocol approved by the Ethics Committee of Qilu Hospital of Shandong University, and were executed according to the *Guide for the Care and Use of Laboratory Animals*, 8th edition (National Research Council of the National Academies, 2011).

Mice were randomly assigned into four groups (n = 6 mice/group). Streptozotocin (STZ, 60 mg/kg; AmyJet, Wuhan, Hubei Province, China) was injected intravenously to mice to induce type 2 diabetes. After 3 days, mice were injected with 10 and 20 mg/kg of picroside II (Leyan Technology, Chengdu, Sichuan Province, China) by intragastric administration once per day for 8 weeks. The body weight and fasting blood glucose were measured at 0, 2, 4, 6 and 8 weeks. After 8 weeks, mice were euthanized by an overdose of chloral hydrate (400 mg/kg; Sigma-Aldrich, USA). The serum and kidney tissues were collected for additional experiments. The rat urine samples were also collected after 8 weeks for urinary protein measurement.

**Hematoxylin and Eosin (H&E) Staining**

The fresh kidney tissues were fixed using 4% paraformaldehyde fix solution (Beyotime, Shanghai, China) at 4°C for 2 days. The fixed tissues were embedded in paraffin wax. The wax was then cut into 5-µm sections and dried on slides. Xylene was used to deparaffinize the wax section, and graded ethanol was used to dehydrate samples. The slides were stained using H&E staining kit (Beyotime) according to manufacturer’s protocol.

**Enzyme-linked immunosorbent assay (ELISA)**

ELISA was used to measure proteinuria, blood urea nitrogen (BUN), serum creatinine (Scr), interleukin (IL)-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1) and necrosis factor alpha (TNF-α) using commercial kits (R&D Systems, Minneapolis, MN, USA) following manufacturer’s instructions.

**Western blotting test**

Total proteins were extracted from the kidney tissues using ProteoPrep® total extraction sample kit (Merck KGaA, Darmstadt, Germany). BCA protein assay kit (Merck KGaA) was used to measure protein concentrations. Proteins were separated using Criterion XT precast gels (Bio-Rad, Hercules, CA, USA) by electrophoresis. Proteins were transferred from gels to polyvinylidene difluoride (PVDF) membranes (Bio-Rad). The membranes were blocked using 5% bovine serum albumin (BSA) blocking buffer (Solarbio Science & Technology Co. Ltd., Beijing, China). The membranes were then incubated with primary antibodies, followed by probing using secondary antibodies. Primary antibodies (Abcam, Cambridge, UK) used in this study were: TLR4 (ab13867, 1:500 dilution), p-65 (ab76302, 1:1000 dilution), p-p65 (ab76302, 1:1000 dilution), p65 (ab16502, 1:800 dilution), IκBα (ab92700, 1:1500 dilution), IκBα (ab32518, 1:1000 dilution), p-p65 (ab76302, 1:1000 dilution), p-p65 (ab76302, 1:1000 dilution), and GAPDH (Glyceraldehyde 3-phosphate dehydrogenase; ab125247, 1:5000 dilution). The protein signals were tested using ECL luminescence reagent (Absin, Shanghai, China) by iBright Imaging Systems (Thermo Fisher Scientific, Madison, WI, USA).

**Statistical analysis**

All results were analyzed using the GraphPad Prism 7.0 software (GraphPad Software, La Jolla, CA, USA). Student’s *t*-test and one-way ANOVA were used to
perform statistical differences between two groups and multiple groups, respectively. All data were presented as mean ± standard deviation. For measurements, $P < 0.05$ was considered statistically significant.

**Results**

**Treatment with picroside II reduced fasting blood glucose levels in mice with diabetic nephropathy**

The body weight was significantly reduced in STZ-induced diabetic mice (Figure 1A). Treatment with picroside II (10 and 20 mg/kg) prevented reduction of bodyweight in STZ-induced diabetic mice (Figure 1A). The fasting blood glucose was elevated in STZ-induced diabetic mice compared to that in the control group (Figure 1B). Treatment with picroside II (10 and 20 mg/kg) inhibited the elevation of fasting blood glucose in STZ-induced diabetic mice (Figure 1B). Therefore, picroside II reduced STZ-induced elevation of fasting blood glucose in mice with diabetic nephropathy.

**Treatment with picroside II lessened kidney injury in mice with diabetic nephropathy**

The levels of proteinuria, BUN and Scr were significantly increased in STZ-induced diabetic mice (Figures 2A–2C). However, treatment with picroside II (10 and 20 mg/kg) reduced the levels of proteinuria, BUN and Scr in STZ-induced diabetic mice (Figures 2A–2C). Treatment with picroside II also lessened morphology damage in mice with diabetic nephropathy (Figure 2D). In STZ-induced diabetic mice, the kidney tissues were seriously damaged due to thickening of glomerular basement membrane (GBM), tubular vacuolization and necrosis, widened renal interstitium and inflammatory cell infiltration (Figure 2D). In diabetic mice treated with picroside II, the glomerular volume was normal, the epithelium of renal tubules was smooth and intact, the arrangement of epithelial cells was regular and the inflammatory cell infiltration was reduced (Figure 2D). Therefore, picroside II lessened kidney injury in mice with diabetic nephropathy.
Picroside II prevents inflammation injury in diabetic nephropathy

Figure 2. Picroside II treatment lessened kidney injury in mice with diabetic nephropathy. (A) Picroside II inhibited the elevation of proteinuria in mice with diabetic nephropathy. (B) Picroside II inhibited the elevation of BUN in mice with diabetic nephropathy. (C) Picroside II inhibited the elevation of Scr in mice with diabetic nephropathy. (D) Picroside II lessened morphological changes in mice with diabetic nephropathy. ***P < 0.005.

Figure 3. Picroside II treatment suppressed inflammatory response in mice with diabetic nephropathy. Picroside II inhibited the elevation of MCP-1, IL-1β, IL-6 and TNF-α in mice with diabetic nephropathy. **P < 0.01; ***P < 0.005.

Treatment with picroside II suppressed inflammatory response through modulation of TLR4/NF-κB pathway in mice with diabetic nephropathy

In mice with diabetic nephropathy, the serum levels of MCP-1, IL-1β, IL-6 and TNF-α were significantly increased (Figure 3). However, treatment with picroside II reduced the serum levels of MCP-1, IL-1β, IL-6 and TNF-α in mice with diabetic nephropathy (Figure 3). Upregulation of TLR4, p-p65 and p-IκBα and down-regulation of IκBα were observed in mice with diabetic nephropathy (Figure 4). Treatment with picroside II
animal model (Kitada et al., 2016). It is a useful model to investigate early alterations in diabetic nephropathy (Kitada et al., 2016). Thus, STZ was used to induce diabetic nephropathy in SD mice. Loss in body weight and elevation in fasting blood glucose were observed in STZ-treated mice, implying the successful construction of diabetic rat model. Treatment with picroside II prevented both loss in body weight and elevation in fasting blood glucose level in STZ-induced diabetic mice, implying the protective effects of picroside II against diabetic nephropathy.

Morphological changes in diabetic nephropathy included thickening of GBM, tubulointerstitial fibrosis, tubular vacuolization and necrosis, and interstitial inflammation (Qi et al., 2017). These changes were also observed in the present study in mice with diabetic nephropathy. Treatment with picroside II lessened these histological changes in kidney tissues in a dose-dependent manner, indicating that picroside II ameliorated kidney injury during diabetic nephropathy. Increase in proteinuria, BUN and Scr are prime indicators of kidney injury during diabetic nephropathy (Tervaert et al., 2010). Administration of picroside II was found to reduce the levels of proteinuria, BUN and Scr in rat with diabetic nephropathy, further confirming that picroside II ameliorated kidney injury during diabetic nephropathy.

Streptozotocin is an antibiotic that can induce pancreatic β-cell damage and is widely used to construct diabetic

Discussion

The activation of inflammatory reaction is a major factor contributing to the progression of diabetic nephropathy (Wada and Makino, 2013). Therefore, inhibition of inflammatory response is an effective solution for the prevention and treatment of diabetic nephropathy. In this study, picroside II was found to prevent reduction in body weight and reversed the elevation of fasting blood glucose level in STZ-induced diabetic mice. Picroside II inhibited morphological damage and parameters of kidney injury, and reduced the production of pro-inflammatory cytokines. Additional experiments also found that picroside II suppressed the activation of TLR4/NF-κB pathway in mice with diabetic nephropathy. Thus, data of this study indicated that picroside II could be a potential complementary therapy for the prevention and treatment of diabetic nephropathy.

NF-κB (p65) is a transcription factor that regulates gene expressions. After stimulation, p65 was phosphorylated...
and IκB kinase was activated, followed by the phosphorylation of IκBα to induce proteasomal degradation of IκBα, leading to the transcription of pro-inflammatory cytokines and cell adhesion molecules (Cai et al., 2021).

In this study, the TLR4/NF-κB pathway was activated due to diabetic nephropathy. Treatment with picroside II suppressed TLR4 expression and phosphorylation of p65 and IκBα, which subsequently upregulated the expression of IκBα, indicating that picroside II prevented the signal transduction of TLR4/NF-κB pathway, which was consistent with previous findings (Wang et al., 2015). Production of cell adhesion molecule (MCP-1) and pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) was also inhibited by picroside II in a dose-dependent manner. Therefore, the anti-inflammatory effect of picroside II was mediated by repression of TLR4/NF-κB pathway in mice with diabetic nephropathy.

In conclusion, picroside II demonstrated its protective effects in STZ-induced diabetic mice by reducing kidney injury indicators and pro-inflammatory cytokines in a dose-dependent manner. Picroside II also lessened morphological damage of kidney tissues in STZ-induced diabetic mice. The anti-inflammatory effect of picroside II was mediated by repression of TLR4/NF-κB pathway, suggesting that picroside II could be a potential anti-inflammatory drug for preventing and treating diabetic nephropathy.

Competing interests

The authors state that there are no conflicts of interest to disclose.

Contribution of authors

Chunmei Ma and Aijie Shi designed the study, and supervised, analyzed and interpreted the data. Both authors prepared, reviewed and approved the final draft of manuscript for publication.

References


